MedImmune

Company snapshot

MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Oncology, Respiratory, Cardiovascular, Renal and Metabolic Disease

• 9 active pipeline program(s) linked via ClinicalTrials.gov.
• 9 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for MedImmune. Not investment advice.

• Peer + 0 momentum

  Regeneron UK

  TA overlap score 50

• Peer + 0 momentum

  GSK Glaxo Smith

  TA overlap score 50

• Peer + 0 momentum

  AstraZeneca

  TA overlap score 40

• Peer + 0 momentum

  AstraZeneca

  TA overlap score 40

• Peer + 0 momentum

  Sunshine Guojian Pharmaceutical

  TA overlap score 40

• Peer + 0 momentum

  Sanofi-Aventis U.S

  TA overlap score 40

• Peer + 0 momentum

  Novartis India

  TA overlap score 40

• Peer + 0 momentum

  Prime Medicine

  TA overlap score 23.4

• Peer + 0 momentum

  Apogee Therapeutics

  TA overlap score 21.6

Recent activity

Latest pipeline, patent, and corporate events for MedImmune.

1. Jun 8, 2026 Clinical update

   Tralokinumab 300 mg, Q2W — Phase 2

2. Jun 8, 2026 Clinical update

   CAIV-T — Phase 2

3. May 26, 2026 Clinical update

   Durvalumab + Oleclumab — Phase 2

4. May 26, 2026 Clinical update

   MEDI8897 — Phase 2

5. May 26, 2026 Clinical update

   MEDI8968 600 mg IV, 300 mg SC — Phase 2

View all clinical trial activity →

• What is MedImmune?

  MedImmune is a pharma organization headquartered in EU. Primary therapeutic focus areas include Respiratory Syncytial Virus Infections, Asthma, Influenza, Stage III Non-small Cell Lung Cancer, Chronic Obstructive Pulmonary Disease. NovaPharmaNews links 9 clinical program(s), 0 dr

• Is MedImmune publicly traded?

  MedImmune appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does MedImmune develop or market?

  We link 7 drug profile(s) where MedImmune is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/medimmune#company-drugs.

• What are the latest developments for MedImmune?

  In the last 12 months our linked public records show 9 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does MedImmune focus on?

  MedImmune focuses on Respiratory Syncytial Virus Infections, Asthma, Influenza based on our analysis of their pipeline programs and drug development activities.